Physician profile
Derrick Deandre Collier
NPI 1386167112
$6,349.91
in general payments reported to CMS, 2019-2025
39 companies · $1,722 in 2025
The $1,722 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,206 · 2022: $1,026 · 2023: $1,202 · 2024: $1,194 · 2025: $1,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,019 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,019.20 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $985.82 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $870.59 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $791.97 | 2021-2025 | |
| Amgen INC. | $651.97 | 2021-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $543.58 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $259.20 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Novartis Pharmaceuticals Corporation | $226.62 | 2022-2025 | |
| Janssen Biotech, INC. | $208.10 | 2024-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.68 | 2022-2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $137.39 | 2023-2025 | Quviviq, Quviviq |
| Pfizer INC. | $134.58 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.93 | 2021-2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $102.98 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.24 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $81.36 | 2023 | Verquvo, Belsomra, Steglatro |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrick Collier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.